February 13, 2017
NOTCH1 mutations defined a subgroup of patients with adenoid cystic carcinomas who harbored an aggressive disease phenotype, demonstrated a distinct pattern of metastatic spread, and who may be responsive to Notch1 inhibitors, according to a study published in Journal of Clinical Oncology.
— common malignant salivary gland tumors — are characterized as a heterogeneous group of chemotherapy-refractory tumors, a subset of which have an aggressive phenotype. No standard of care exists for patients with recurrent or metastatic disease.
“Whole-exome sequencing of adenoid cystic carcinomas samples has shed light on the genetic landscape of this disease and provides evidence for Notch pathway alterations in 11% to 29% of patients,” Renata Ferrarotto, MD, assistant professor in the department of thoracic/head and neck medical oncology at The University of Texas MD Anderson Cancer Center, and colleagues wrote. “The Notch pathway is involved in cancer-relevant functions, including maintenance of stem cells, cell fate specification, proliferation and angiogenesis.”